Nicholas Investment Partners, LP Bei Gene, Ltd. Transaction History

Nicholas Investment Partners, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $1.88 Million - $2.32 Million	-15,299 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$107.01 - $175.15 $939,868 - $1.54 Million	-8,783 Reduced 36.47%	15,299 $2.15 Million
Q3 2018 Nov 14, 2018	SELL	$152.62 - $189.66 $157,045 - $195,160	-1,029 Reduced 4.1%	24,082 $4.15 Million
Q2 2018 Aug 14, 2018	BUY	$152.5 - $216.77 $3.83 Million - $5.44 Million	25,111 New	25,111 $3.86 Million

216

42M

106K

93.1K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $21B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.